Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Time for T

Graeme Moyle1

  • 1Chelsea & Westminster Hospital, London, UK.

The AIDS Reader
|July 26, 2002
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteers.

HIV medicine·2026
Same author

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation.

AIDS (London, England)·2026
Same author

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.

AIDS (London, England)·2025
Same author

Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.

Journal of acquired immune deficiency syndromes (1999)·2025
Same author

Antiretrovirals and Weight Change: Weighing the Evidence.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

The lancet. HIV·2024
Same journal

Effect of antiretroviral resistance on response in treatment-experienced patients.

The AIDS reader·2009
Same journal

Maximizing treatment outcome: key considerations for antiretroviral-experienced patients.

The AIDS reader·2009
Same journal

Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management.

The AIDS reader·2009
Same journal

Economic crisis threatens AIDS fight.

The AIDS reader·2009
Same journal

Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?

The AIDS reader·2009
Same journal

Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.

The AIDS reader·2009
See all related articles